Literature DB >> 11489827

Fluorescence in situ hybridization evaluation of c-erbB-2 gene amplification and chromosomal anomalies in bladder cancer.

J I Ohta1, Y Miyoshi, H Uemura, K Fujinami, K Mikata, M Hosaka, Y Tokita, Y Kubota.   

Abstract

Oncogene amplification and chromosomal anomalies are found in many solid tumors and are often associated with aggressiveness of cancer. We evaluated the frequency and the role of c-erbB-2 gene amplification, relative increase in c-erbB-2 gene copy number, and gain of chromosome 17 in bladder cancer. A total of 29 bladder cancer specimens were examined using fluorescence in situ hybridization (FISH). Dual labeling hybridization with a directly labeled centromere probe for chromosome 17 together with a probe for the c-erbB-2 locus was performed. c-erbB-2 gene amplification was found in 3.4% (1 of 29) of specimens. Relative increase in c-erbB-2 gene copy number was found in 41.4% (12 of 29) of specimens and was significantly associated with tumor grade (P = 0.044 by Fisher's exact test). Gain of chromosome 17 was identified in 65.5% (19 of 29) of specimens and was significantly associated with tumor grade (P = 0.002 by Fisher's exact test) and tumor stage (P = 0.003 by Fisher's exact test). Our results suggest that c-erbB-2 gene amplification, relative increase in c-erbB-2 gene copy number, and gain of chromosome 17 may play important roles in the development and progression of bladder cancers. Moreover, the use of c-erbB-2 amplification, relative increase in c-erbB-2 gene copy number, and gain of chromosome 17 using FISH, together with tumor grade and stage, may provide a more useful clinical indicator in bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11489827

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  7 in total

1.  Overexpression of PTK6 (breast tumor kinase) protein--a prognostic factor for long-term breast cancer survival--is not due to gene amplification.

Authors:  Michaela Aubele; Sanja Vidojkovic; Herbert Braselmann; Dominique Ritterswürden; Gert Auer; Mike J Atkinson; Soile Tapio; Heinz Höfler; Sandra Rauser; John M S Bartlett
Journal:  Virchows Arch       Date:  2009-07-21       Impact factor: 4.064

2.  No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas.

Authors:  Vildan Caner; Nilay Sen Turk; Fusun Duzcan; N Lale Satiroglu Tufan; E Canan Kelten; Sevil Zencir; Yavuz Dodurga; Huseyin Bagci; S Ender Duzcan
Journal:  Pathol Oncol Res       Date:  2008-04-16       Impact factor: 3.201

3.  Mapping of the chromosomal amplification 1p21-22 in bladder cancer.

Authors:  Mauro Scaravilli; Paola Asero; Teuvo L J Tammela; Tapio Visakorpi; Outi R Saramäki
Journal:  BMC Res Notes       Date:  2014-08-18

Review 4.  Different stages in drug development for muscle-invasive bladder cancer.

Authors:  Gallus Beatus Ineichen; Raphael Röthlisberger; Kevin Fabian Johner; Roland Seiler
Journal:  Transl Androl Urol       Date:  2017-12

5.  Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy.

Authors:  Bernhard Kiss; Alexander W Wyatt; James Douglas; Veronika Skuginna; Fan Mo; Shawn Anderson; Diana Rotzer; Achim Fleischmann; Vera Genitsch; Tetsutaro Hayashi; Maja Neuenschwander; Christine Buerki; Elai Davicioni; Colin Collins; George N Thalmann; Peter C Black; Roland Seiler
Journal:  Sci Rep       Date:  2017-02-16       Impact factor: 4.379

6.  Genomic and transcriptomic analyses reveal a tandem amplification unit of 11 genes and mutations in mismatch repair genes in methotrexate-resistant HT-29 cells.

Authors:  Ahreum Kim; Jong-Yeon Shin; Jeong-Sun Seo
Journal:  Exp Mol Med       Date:  2021-09-14       Impact factor: 12.153

7.  Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer.

Authors:  Ildikó Kocsmár; Éva Kocsmár; Gábor Pajor; Janina Kulka; Eszter Székely; Glen Kristiansen; Oliver Schilling; Péter Nyirády; András Kiss; Zsuzsa Schaff; Péter Riesz; Gábor Lotz
Journal:  Cancers (Basel)       Date:  2022-09-21       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.